Protocol for Recovery of Measles Virus from Intact/Recombinant Antigenomic DNA | ||
| Pathobiology Reserach | ||
| Article 6, Volume 24, Issue 1, 2021, Pages 45-54 PDF (959 K) | ||
| Document Type: Original Research | ||
| Authors | ||
| roghayeh alizadeh1; Kayhan Azadmanesh* 2; Arash Arashkia2; Mostafa Ghanei3 | ||
| 1Baghyatollah Medical Sciences University | ||
| 2Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran | ||
| 3Baghyatollah Medical Sciences University,Chemical Injuries Research Center | ||
| Abstract | ||
| Measles virus, negative-strand RNA viruses, has been known as an ideal candidate in oncolytic virotherapy. Recombinant measles virus can encode genes of interests for reaching several aims. Replication efficiency of oncolytic virus in tumoral cells is a key parameter in efficient tumor eradication. Products of P gene (P/V/C) support measle virus to circumvent IFN 1 as the main response of innate immune system against viruses. But vaccine strains used in oncolytic therapy studies comprise several mutations in their P gene sequences. These mutations affect replication efficacy which cause attenuation of measles strains applicable in vaccination. So, arming vaccine strains with the wild type P gene is helpful to reach high virus titer. Here at this study, we have expanded a protocol with details for engineering and efficient recovery of measles virus for different aims. | ||
| Keywords | ||
| Key Words: Measles Virus; Reverse Genetics; Viral Rescue; Oncolytic Virotherapy | ||
| References | ||
|
| ||
|
Statistics Article View: 111 PDF Download: 60 |
||
| Number of Journals | 45 |
| Number of Issues | 2,171 |
| Number of Articles | 24,674 |
| Article View | 24,444,847 |
| PDF Download | 17,554,034 |